• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Aflibercept Biosimilar Improves Vision and Clears Retinal Fluid in Indian Study

by
November 18, 2026
in Health
Reading Time: 6 mins read
0
Aflibercept Biosimilar Improves Vision and Clears Retinal Fluid in Indian Study

Aflibercept Biosimilar Improves Vision and Clears Retinal Fluid in Indian Study

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A multicentre retrospective observational study across five tertiary retina centres in India has shown that a single intravitreal injection of Anyra, a novel aflibercept biosimilar, produced significant visual and anatomical improvements in treatment-naïve retinal diseases. Published in Ophthalmology and Therapy, the investigation evaluated one hundred and sixty-two consecutive treatment-naïve eyes from one hundred and sixty-two patients treated between April 2026 and May 2026. The clinical cohort comprised individuals presenting with neovascular age-related macular degeneration, diabetic macular oedema, retinal vein occlusion, or myopic macular neovascularization. Over a standard one-month post-injection follow-up period, the biosimilar was associated with substantial reductions in central macular thickness, widespread clearance of intraretinal and subretinal fluid, and statistically significant gains in best-corrected visual acuity across major disease subgroups. The investigators recorded no ocular or systemic adverse events during follow-up, providing initial real-world evidence for this therapeutic biological alternative in routine clinical ophthalmic practice.

Neovascular age-related macular degeneration, diabetic macular oedema, and macular oedema secondary to retinal vein occlusion represent leading causes of visual impairment worldwide. Standard clinical management relies on intravitreal inhibition of vascular endothelial growth factor, which suppresses exudative retinal activity and improves vision. Aflibercept is a recombinant fusion protein acting as a soluble decoy receptor that binds vascular endothelial growth factor-A, vascular endothelial growth factor-B, and placental growth factor. Its therapeutic efficacy was established in pivotal trials, including VIEW 1 and VIEW 2 for neovascular age-related macular degeneration, VIVID and VISTA for diabetic macular oedema, and COPERNICUS and GALILEO for central retinal vein occlusion. However, chronic recurrence frequently requires repeated injections and continuous monitoring, imposing substantial financial and logistical burdens. In settings characterized by high out-of-pocket healthcare costs and limited reimbursement, expense and travel distance often contribute to delayed presentation, missed clinic appointments, and persistent under-treatment across vulnerable patient populations.

Biosimilars are regulated biological medicines displaying high similarity to an approved reference biologic, with no clinically meaningful differences in quality, safety, or clinical effectiveness. Their regulatory development demands exhaustive analytical comparability, non-clinical evaluation, and clinical confirmation within established statutory guidelines. Formal approval does not necessitate independent replication of every indication-specific trial conducted for the reference originator, provided the totality of comparability data supports scientific extrapolation across approved indications. In ophthalmology, aflibercept biosimilars such as SB15, P041, and MYL-1701P have demonstrated comparable visual, anatomical, pharmacokinetic, and immunogenicity profiles in randomized phase three trials. Controlled clinical trials, however, do not reflect real-world treatment environments involving broad disease heterogeneity, variable clinic follow-up, and everyday operational challenges. Evaluating early real-world clinical experience in India—where previous adoption of ranibizumab biosimilars broadened treatment access—provides critical post-marketing insight into clinical outcomes under routine healthcare conditions across diverse real-world patient populations seeking affordable targeted biological therapies.

The multicentre observational investigation reviewed clinical records from five tertiary retina facilities in India. Institutional review board approval was secured from the Retina Institute of Bengal Ethics Committee in Siliguri, India, under protocol RIB/IRB/0002/2026, with all procedures conforming to the Declaration of Helsinki and all patients granting written informed consent. The study enrolled one hundred and sixty-two treatment-naïve patients presenting with a mean age of 61.31 ± 12.84 years. Patient and attender demographic records identified eighty-four male participants (51.9 percent) and seventy-eight female participants (48.1 percent), with all subjects identified ethnically as South Asian Indians. The clinical cohort included eighty-two eyes with neovascular age-related macular degeneration, forty eyes with centre-involving diabetic macular oedema, thirty-six eyes with macular oedema due to retinal vein occlusion, and four eyes with myopic macular neovascularization. Within the retinal vein occlusion subgroup, twenty eyes presented with branch occlusion and sixteen eyes presented with central occlusion.

Eligible eyes required documented baseline examinations and complete one-month post-treatment follow-up evaluations including best-corrected visual acuity measurement and spectral-domain optical coherence tomography scans. Eyes were excluded if they had received prior intravitreal anti-vascular endothelial growth factor injections, intravitreal corticosteroids, macular laser photocoagulation, or vitreoretinal surgery for the target disease. The researchers also excluded eyes exhibiting coexisting retinal disorders or significant media opacities that could interfere with image interpretation or vision testing. Polypoidal choroidal vasculopathy was an explicit exclusion criterion, ensuring the neovascular macular degeneration subgroup did not contain polypoidal lesions. Treatment was administered under aseptic conditions in the operating room, delivering a standard dose of 2 mg in 0.05 mL of the aflibercept biosimilar via routine intravitreal injection technique.

Primary clinical outcomes encompassed changes in visual acuity converted to logarithm of the minimum angle of resolution notation, central macular thickness measured in micrometres, resolution of fluid compartments, and complete retinal drying. Fluid resolution was defined as the total absence of fluid at one month in eyes presenting with fluid at baseline. Complete retinal drying was defined as the concurrent absence of both intraretinal and subretinal fluid on optical coherence tomography. Baseline and one-month continuous variables, expressed as mean ± standard deviation, were compared using two-sided paired Student t-tests, while binary categorical transitions were assessed using McNemar tests with continuity correction. Analyses were performed using IBM SPSS Statistics version 23.0, setting statistical significance at a P-value below 0.05. Disease-specific analyses evaluated neovascular macular degeneration, diabetic macular oedema, and retinal vein occlusion, whereas the four myopic macular neovascularization eyes were analyzed descriptively due to their very small sample size.

Across the entire cohort of one hundred and sixty-two eyes, treatment produced statistically significant functional improvements and anatomical decongestion at the one-month evaluation. Mean best-corrected visual acuity improved from 0.77 ± 0.40 logMAR at baseline to 0.55 ± 0.39 logMAR at one month, reflecting a mean improvement of −0.22 ± 0.26 logMAR (P < 0.001). Concurrently, optical coherence tomography scans documented a pronounced decline in central macular thickness, which decreased from 480.67 ± 207.8 µm at baseline to 309.13 ± 163.4 µm after thirty days. This anatomical change represented an overall mean thickness reduction of 171.54 ± 170.8 µm (P < 0.001). These concurrent gains in visual clarity and retinal structural architecture demonstrated an immediate therapeutic biological effect following a single biosimilar administration in previously untreated retinal disorders across multiple participating tertiary retina centres, confirming favourable short-term responsiveness although the non-randomized retrospective observational design naturally precluded formal causal determinations.

Evaluation of optical coherence tomography fluid compartments revealed significant resolution of exudative pathology across the patient cohort. Intraretinal fluid was present in one hundred and twenty eyes (74.1 percent) at baseline and declined to forty eyes (24.7 percent) at one month (P < 0.001), representing successful fluid resolution in eighty-one of one hundred and twenty eyes (67.5 percent resolution rate), with newly developed intraretinal fluid documented in only one eye. Subretinal fluid decreased from eighty-two eyes (50.6 percent) at baseline to thirty-three eyes (20.4 percent) at follow-up (P < 0.001), achieving resolution in forty-nine of eighty-two eyes (59.8 percent resolution rate) without any eye developing new subretinal fluid. Complete retinal drying, defined as the absence of both fluid types, was achieved in ninety-six eyes, or 59.3 percent of the entire cohort, demonstrating substantial short-term exudative control across diverse retinal indications in routine everyday outpatient ophthalmic clinical care settings.

Disease-specific subgroup evaluations demonstrated consistent functional and structural benefits across all primary indications. In neovascular macular degeneration (eighty-two eyes), visual acuity improved from 0.79 ± 0.39 to 0.61 ± 0.40 logMAR, central macular thickness decreased by 151.04 ± 127.50 µm, and complete retinal drying occurred in 51.2 percent (P < 0.001). In diabetic macular oedema (forty eyes), vision improved from 0.66 ± 0.28 to 0.49 ± 0.30 logMAR, thickness decreased by 80.55 ± 108.14 µm, and drying reached 75.0 percent (P < 0.001). In retinal vein occlusion (thirty-six eyes: twenty branch, sixteen central), vision improved from 0.85 ± 0.50 to 0.48 ± 0.46 logMAR with a thickness reduction of 323.44 ± 221.02 µm (P < 0.001) and 58.3 percent complete drying. In four descriptive myopic neovascularization eyes, vision improved from 0.79 ± 0.36 to 0.48 ± 0.38 logMAR with three achieving complete drying. Multimodal imaging illustrated these findings, including an 80-year-old man with neovascular macular degeneration improving from 20/80 to 20/32 and a 57-year-old woman with central retinal vein occlusion whose macular thickness dropped from 856 µm to 247 µm with vision improving from 20/120 to 20/32.

Safety surveillance throughout the one-month post-injection follow-up period identified zero ocular or systemic adverse events. The investigation recorded no cases of intraocular inflammation, retinal vasculitis, infectious endophthalmitis, sustained intraocular pressure elevation, retinal detachment, or systemic thromboembolic complications across the treated cohort. However, the authors noted several critical limitations inherent to their retrospective observational framework. The single-arm design lacked a concurrent reference aflibercept comparator, precluding determinations of therapeutic equivalence, non-inferiority, or regulatory interchangeability. Follow-up was restricted to thirty days after a single injection, preventing evaluation of long-term visual maintenance, injection durability, or rare delayed adverse reactions. Furthermore, baseline records lacked detailed data regarding pre-treatment symptom duration, exact chronicity of macular oedema, referral intervals, and specific neovascular lesion phenotypes. Because pre-treatment chronicity influences anatomical responsiveness, these early findings should be interpreted cautiously. Nevertheless, these multicentre real-world outcomes support further prospective clinical trials to define the long-term utility of aflibercept biosimilars in expanding affordable ophthalmic therapy.

Subject of Research: Early real-world clinical outcomes of the aflibercept biosimilar Anyra in treatment-naïve retinal diseases

Article Title: Early Multicentre Real-World Outcomes of AnyraTM, a Novel Aflibercept Biosimilar, in Treatment-Naïve Retinal Diseases

Article References: Chakraborty, S., Sheth, J. U., Sudhalkar, A., Kanungo, S., Sinha, S., & Narnaware, S. (2026). Early Multicentre Real-World Outcomes of AnyraTM, a Novel Aflibercept Biosimilar, in Treatment-Naïve Retinal Diseases. Ophthalmology and Therapy. https://doi.org/10.1007/s40123-026-01538-3

Image Credits: AI Generated

DOI: 10.1007/s40123-026-01538-3

Keywords: aflibercept biosimilar, Anyra, neovascular age-related macular degeneration, diabetic macular oedema, retinal vein occlusion, myopic macular neovascularization, central macular thickness, best-corrected visual acuity, intraretinal fluid, subretinal fluid, complete retinal drying, intravitreal injection, vascular endothelial growth factor, optical coherence tomography, retina centres, ophthalmology, treatment-naïve eyes, real-world outcomes

News Source: Ophelia Keating. (November 18, 2026). Aflibercept Biosimilar Improves Vision and Clears Retinal Fluid in Indian Study. Scienmag.

Tags: aflibercept biosimilarAnyrabest-corrected visual acuitycentral macular thicknesscomplete retinal dryingdiabetic macular oedemaIntraretinal Fluidintravitreal injectionmyopic macular neovascularizationneovascular age-related macular degenerationOphthalmologyoptical coherence tomographyreal-world outcomesretina centresretinal vein occlusionsubretinal fluidtreatment-naive eyesvascular endothelial growth factor
Share12Tweet7Share2ShareShareShare1

Related Posts

Stronger Clinical Trial Evidence Increases Reimbursement Odds for Chinese Patent Medicines

Stronger Clinical Trial Evidence Increases Reimbursement Odds for Chinese Patent Medicines

November 18, 2026
Liver Cancer Stage Explains Apparent Survival Advantage in Female Patients

Liver Cancer Stage Explains Apparent Survival Advantage in Female Patients

November 18, 2026

Divorce Is Associated With Higher Suicide Mortality in Prostate Cancer Survivors

November 18, 2026

Lecanemab Shows Cognitive Stability and Amyloid Clearance in Chinese Alzheimer’s Cohort

November 18, 2026

POPULAR NEWS

  • Elite Luge Athletes Experience Seasonal Shifts in Body Composition and Biomarkers

    Elite Luge Athletes Experience Seasonal Shifts in Body Composition and Biomarkers

    29 shares
    Share 12 Tweet 7
  • Olive Oil Supplementation Remodels Plasma Lipids and Metabolites in Aged Tauopathy Mice

    29 shares
    Share 12 Tweet 7
  • Mitophagy Inhibitor Ac220 Enhances Magnolol Antitumor Action in Ewing Sarcoma

    29 shares
    Share 12 Tweet 7
  • Systematic Review Finds Long-Term Data Scarce for Chronic Neuropathic Pain Treatments

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Biaxial Strain Drives Bandgap Closure and Boosts Optical Absorption in Monolayer MoS2

Stronger Clinical Trial Evidence Increases Reimbursement Odds for Chinese Patent Medicines

Social Force Guided Neural Network Improves Pedestrian Trajectory Predictions in Tests

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.